An anti‐PD‐1 monoclonal antibody that binds with high affinity to the PD‐1 receptor and effectively blocks interaction with PD‐L1 and PD‐L2, restoring cytotoxic T‐cell activity and freeing the T‐cell to kill tumour cells. Here, PDCD1LG2 is linked to neoplasm.